Pulse Biosciences to present data on NPS technology for treating nBCC
Category: #health  By Pankaj Singh  Date: 2020-01-31
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Pulse Biosciences to present data on NPS technology for treating nBCC

Pulse Biosciences Inc., a bioelectric medicine company, has reportedly announced that it will be presenting its scientific study assessing the clinical and histologic response of NPS™(Nano-Pulse Stimulation™) technology in treating critical cases of nodular nBCC (Basal Cell Carcinoma).

These outcomes are to be presented at the 22nd annual International Master Course on Aging Skin (IMCAS) World Congress, which apparently is the meeting of international experts in plastic surgery, dermatology, and aging science which will meet in Palais des Congrès, Paris, France.

As per sources, the results show the unique ability of NPS technology to remove tumor cells in nBCCs while sparing surrounding healthy tissue. These outcomes will be backed by clinical photos that display favorable cosmetic outcome possible in a short period with reduced potential for scar development as compared to present surgical excision.

The nBCC subtype reported in this study includes 60% of all basal cell carcinomas. Surgical excision is the present standard care of these nodular lesions which can lead to permanent large scars.

Speaking on the data, Dr. Girish Munavalli of Dermatology, Laser & Vein experts of the Carolinas, Charlotte, NC, said that early findings demonstrated promising potential for NPS technology as a novel treatment option for nBCC.

NPS technology has shown similar therapeutic benefit and the added benefit of superior cosmetic results compared to destructive skin cancer treatment modalities, like curettage and excision.

As per Darrin Uecker, CEO and President of Pulse Biosciences, their company is enthusiastic about the impressive results NPS technology is demonstrating in Basal Cell Carcinomas. They are focused on rapidly advancing its development program across multiple clinical applications.

Uecker added that the company’s presence at the IMCAS conference represented its commitment to international commercialization, which aims to extend Pulse’s long-term growth platform and leverage the Nano-Pulse Stimulation Technology to clear malignant and benign lesions.
 

Source Credit - http://investors.pulsebiosciences.com/news-releases/news-release-details/pulse-biosciences-present-data-nano-pulse-stimulation-technology



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

The Bay collaborates with Rebelstork for gently used baby gear resale

The Bay collaborates with Rebelstork for gently used baby gear resale

By Pankaj Singh

Iconic retailer of Canada, The Bay has reportedly entered into a resale partnership with Rebelstork, a Canadian startup. Rebelstork is the first administered marketplace in North America for the resale of open box, qua...

Datopotamab Deruxtecan exhibits good tumor response in NSCLC patients

Datopotamab Deruxtecan exhibits good tumor response in NSCLC patients

By Pankaj Singh

According to new data for Dato-DXd (datopotamab deruxtecan), a DXd ADC (antibody drug conjugate) directed by TROP2 has reportedly showcased favorable tumor response rate in advanced NSCLC (non-small cell lung cancer) p...

Candy Club© reinforces retail commitment with new wholesale website

Candy Club© reinforces retail commitment with new wholesale website

By Pankaj Singh

Candy Club©, a growing candy brand that provides premium candy flavors with colorful packaging, has reportedly announced the launch of a new website for wholesale consumers to buy its products directly ...